445 related articles for article (PubMed ID: 33524139)
1. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
Ramadan HK; Badr G; Ramadan NK; Sayed A
Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
[TBL] [Abstract][Full Text] [Related]
5. lnc-HOTAIR predicts hepatocellular carcinoma in chronic hepatitis C genotype 4 following direct-acting antivirals therapy.
El-Khazragy N; Elshimy AA; Hassan SS; Shaaban MH; Bayoumi AH; El Magdoub HM; Ghozy S; Gaballah A; Aboelhussein MM; Abou Gabal HH; Bannunah AM; Mansy AE
Mol Carcinog; 2020 Dec; 59(12):1382-1391. PubMed ID: 33074585
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
Amaddeo G; Nguyen CT; Maillé P; Mulé S; Luciani A; Machou C; Rodrigues A; Regnault H; Mallat A; Laurent A; Lafdil F; Hézode C; Pawlotsky JM; Calderaro J
Liver Int; 2020 Jan; 40(1):74-82. PubMed ID: 31444947
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
8. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
[TBL] [Abstract][Full Text] [Related]
9. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
10. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
13. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
14. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy.
Li H; Huang MH; Jiang JD; Peng ZG
World J Gastroenterol; 2018 Dec; 24(47):5297-5311. PubMed ID: 30598575
[TBL] [Abstract][Full Text] [Related]
16. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
19. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]